SABCS 2017: Sacituzumab Govitecan as Late Therapeutic Option in Metastatic Breast Cancer
Sacituzumab govitecan (IMMU-132) was found to be effective as a third-line or later therapy for patients with relapsed or refractory metastatic triple-negative breast cancer. This finding was based on data from a phase I/II basket trial presented at the 2017 San Antonio Breast Cancer Symposium (SABCS; Abstract GS1-07) by Aditya Bardia, MD, MPH, of the Dana-Farber/Harvard Cancer Center at Massachusetts General Hospital, Boston, and colleagues.
Between 2013 and 2017, 110 patients with metastatic triple-negative breast cancer (109 women, 1 man) were treated with sacituzumab govitecan. The objective response rate was 34%. The median progression-free survival was 5.5 months, with 11 patients experiencing long-term progression-free survival of 12 to 30+ months. The median overall survival was 12.7 months. Treatment was well tolerated, with no treatment-related deaths reported.
Sacituzumab govitecan consists of SN-38—the active metabolite of the topoisomerase I inhibitor irinotecan—conjugated to a humanized monoclonal antibody that targets Trop-2, also known as tumor-associated calcium signal transducer. A global confirmatory randomized phase III trial (ASCENT study) of this agent in this patient population is underway (ClinicalTrials.gov identifier NCT02574455).